Scholarlink

<p>Our study assessed the cost-effectiveness of screening for hepatic fibrosis in cases suspected of metabolic dysfunction-associated steatotic liver disease (MASLD) using serological noninvasive tests like the fatty liver index (FLI) and hepatic steatosis index (HSI). We applied a decision tree and Markov model from a healthcare system perspective to estimate life-years, quality-adjusted life-years (QALYs), costs, and the incremental cost-effectiveness ratio (ICER) for screening versus no screening in the United States. Prevalence of advanced hepatic fibrosis in individuals suspected of having MASLD was significantly higher when defined by FLI (10.6% vs. 1.3%, <i>P</i> &lt; 0.001) and HSI (8.6% vs. 2.2%, <i>P</i> &lt; 0.001), compared to those without MASLD. Screening (base case) for suspected MASLD defined by FLI had an ICER of $78,647 per QALY and by HSI, $84,874 per QALY, both of which were considered cost-effective based on the implicit ICER threshold of $100,000/QALY in the United States. However, screening for other subgroups without evidence of MASLD was not deemed cost-effective. When applying medical costs and fibrosis distribution data from Korea, similar results were observed. Implementing a two-step screening algorithm for advanced hepatic fibrosis in patients with suspected MASLD based on HSI or FLI calculation is cost-effective in primary care settings.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Cost-effectiveness of advanced hepatic fibrosis screening in individuals with suspected MASLD identified by serologic noninvasive tests

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月7日

查看全文
  • Huiyul Park,
  • Eileen L. Yoon,
  • Mimi Kim,
  • Ji-hyeon Park,
  • Ramsey Cheung,
  • Jeong-Yeon Cho,
  • Hye-Lin Kim,
  • Dae Won Jun

摘要

Our study assessed the cost-effectiveness of screening for hepatic fibrosis in cases suspected of metabolic dysfunction-associated steatotic liver disease (MASLD) using serological noninvasive tests like the fatty liver index (FLI) and hepatic steatosis index (HSI). We applied a decision tree and Markov model from a healthcare system perspective to estimate life-years, quality-adjusted life-years (QALYs), costs, and the incremental cost-effectiveness ratio (ICER) for screening versus no screening in the United States. Prevalence of advanced hepatic fibrosis in individuals suspected of having MASLD was significantly higher when defined by FLI (10.6% vs. 1.3%, P < 0.001) and HSI (8.6% vs. 2.2%, P < 0.001), compared to those without MASLD. Screening (base case) for suspected MASLD defined by FLI had an ICER of $78,647 per QALY and by HSI, $84,874 per QALY, both of which were considered cost-effective based on the implicit ICER threshold of $100,000/QALY in the United States. However, screening for other subgroups without evidence of MASLD was not deemed cost-effective. When applying medical costs and fibrosis distribution data from Korea, similar results were observed. Implementing a two-step screening algorithm for advanced hepatic fibrosis in patients with suspected MASLD based on HSI or FLI calculation is cost-effective in primary care settings.